|
|
Post by sla55 on Mar 7, 2023 17:06:33 GMT -5
investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-oppenheimer-33rd-annual
MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 2:00 pm (ET). Interested parties can access a link to the webcast from the News & Events section of the Company’s website at Events & Presentations. The webcast replay will remain available for 14 days following the live presentation.
|
|
|
|
Post by cppoly on Mar 13, 2023 12:55:43 GMT -5
Any thoughts on tomorrow's conference?
Both UTHR and MNKD are presenting.
|
|
|
|
Post by JEvans on Mar 13, 2023 13:50:57 GMT -5
UTHR already presented. It was very good. UTHR is very focused, very organized, very well spoken.
|
|
|
|
Post by mymann on Mar 14, 2023 14:53:51 GMT -5
Mike, stop going to conferences if you have nothing to say. It just drops the sp.
|
|
|
|
Post by lennymnkd on Mar 14, 2023 15:20:39 GMT -5
Are you taking for granted what Mike is putting together with DEXCOM / ABC
|
|
|
|
Post by cretin11 on Mar 14, 2023 15:36:32 GMT -5
lenny what are the details of that, or what should we expect the details to be (and when)?
|
|
|
|
Post by lennymnkd on Mar 14, 2023 15:46:21 GMT -5
Sounded pretty technical.. in its initial stages .. he speaks of it early on in the call ..worth a listen
Going to give it a second listen .bluehale and Dexcom integrating its platform because of its api
Open source
Learn how to use our API to build your diabetes app. The Dexcom API enables the development of innovative apps that amplify the value and utility of CGM ...
|
|
|
|
Post by brianrocco on Mar 14, 2023 17:29:00 GMT -5
Mike seemed to imply that the price cuts by Lilly and Novo Nordisk could help Afrezza. Can someone explain his logic?
I accept Mike's implication that the price cuts will hurt the PBMs more than the drug manufacturers. It would seem that the price cuts will reduce the dollars flowing from the uninsured and underinsured to the PBMs and the health insurers via the PBMs. But Afrezza prices for the uninsured, underinsured and health insurers will be even higher relative to the repriced insulin products from Lilly and Novo Nordisk.
Many thanks anyone.
|
|
|
|
Post by Thundersnow on Mar 14, 2023 17:36:18 GMT -5
It's amazing how the stock price DROPS around the time STOCK OPTIONS are issued. Expect the S-4's soon. Is this a coincidence or is it planned??? LOL
|
|
|
|
Post by beardawg on Mar 16, 2023 17:00:05 GMT -5
Mike seemed to imply that the price cuts by Lilly and Novo Nordisk could help Afrezza. Can someone explain his logic? I accept Mike's implication that the price cuts will hurt the PBMs more than the drug manufacturers. It would seem that the price cuts will reduce the dollars flowing from the uninsured and underinsured to the PBMs and the health insurers via the PBMs. But Afrezza prices for the uninsured, underinsured and health insurers will be even higher relative to the repriced insulin products from Lilly and Novo Nordisk. Many thanks anyone. Afrezza was locked out of some PBMs' drug list because Novo/Lilly made agreements of exclusivity, in exchange for rebates. Now that they won't be rebating the PBMs, there will be no incentive for the PBMs to lock other competing drugs out. So, Afrezza will now have a level playing field. |
|
|
|
Post by agedhippie on Mar 16, 2023 17:36:15 GMT -5
Afrezza was locked out of some PBMs' drug list because Novo/Lilly made agreements of exclusivity, in exchange for rebates. Now that they won't be rebating the PBMs, there will be no incentive for the PBMs to lock other competing drugs out. So, Afrezza will now have a level playing field. Novo/Lilly can use the other drugs they sell. Give us exclusivity on our insulin (and other drugs) and we will give you a better rebate on Ozempic/Trulicity... The PBM will be looking at the big picture and not single drugs. |
|
|
|
Post by awesomo on Mar 22, 2023 14:12:29 GMT -5
|
|
|
|
Post by JEvans on Mar 22, 2023 17:39:06 GMT -5
On that slide presentation page 4, I wonder why Mike said this We ended 2022 with:
– 2 marketed products on our platform (Afrezza & Tyvaso DPI)+ V-Go®
I think he should have said, 3 marketed products. I know I can count to three, but you never know.... |
|
|
|
Post by agedhippie on Mar 22, 2023 17:57:45 GMT -5
On that slide presentation page 4, I wonder why Mike said this We ended 2022 with:
– 2 marketed products on our platform (Afrezza & Tyvaso DPI)+ V-Go®
I think he should have said, 3 marketed products. I know I can count to three, but you never know.... Better emphasis would be: – 2 marketed products on our platform (Afrezza & Tyvaso DPI) + V-Go® or phrased as: – 2 marketed products on our platform (Afrezza & Tyvaso DPI), and V-Go® |
|
|
|
Post by JEvans on Mar 22, 2023 18:16:22 GMT -5
My point was, isn't that 3 products ?
|
|
